Ecnoglutide

埃诺格鲁肽

Report date: 2026/04/28 20:00:22

Base Information

Drug NameEcnoglutide
Drug Alias Name伊诺格鲁肽先颐达先维盈XW-003
ClassificationBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionGlucagon-like peptide 1 receptor agonists
TargetsGlucagon-like peptide 1 receptor
Therapy Area/IndicationsOverweightBody WeightObesity +[8] 
Global Approved IndicationsDiabetes Mellitus, Type 2
Approved Indications in ChinaDiabetes Mellitus, Type 2
Original Approved Country/TerritoryMainland China
Original Approved Date2026/01/27
Country/TerritoryAustraliaMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesHangzhou Sciwind Biotechnology Co LtdBeijing Kawin Technology Share-Holding Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesVerdiva Bio LtdSciwind Biosciences APAC Co Pty LtdHK inno.N Corporation +[4] 
Inactive CompaniesAmphastar Nanjing Pharmaceuticals Inc
Active IndicationsOverweightBody WeightObesity +[8] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksWikipedia